Systemic treatment of psoriasis: from methotrexate to biologics

التفاصيل البيبلوغرافية
العنوان: Systemic treatment of psoriasis: from methotrexate to biologics
المؤلفون: E. M. Anpilogova, Olga Yu. Olisova
المصدر: Vestnik Dermatologii i Venerologii, Vol 96, Iss 3, Pp 7-26 (2020)
بيانات النشر: State Scientific Center of Dermatovenereology and Cosmetology, 2020.
سنة النشر: 2020
مصطلحات موضوعية: medicine.medical_specialty, Dermatology, 030207 dermatology & venereal diseases, 03 medical and health sciences, 0302 clinical medicine, Psoriasis, Ustekinumab, medicine, Adalimumab, Intensive care medicine, business.industry, psoriasis, systemic treatment, medicine.disease, Infliximab, humanities, Ixekizumab, small molecules, Infectious Diseases, Guselkumab, biological therapy, 030220 oncology & carcinogenesis, RL1-803, Secukinumab, Apremilast, business, medicine.drug
الوصف: Psoriasis is one of the most frequent chronic inflammatory skin diseases and it has been of interest to many scientists for ages. The review presents data on all systemic treatment options, that are to date officially registered in Russian Federation for moderate-to-severe psoriasis. Aspects of the mechanism of action, efficacy and tolerability of both basic drugs (methotrexate, cyclosporine, acitretin) and biologics (infliximab, adalimumab, etanercept, certolizumab pegol, ustekinumab, guselkumab, secukinumab, ixekizumab, netakimab) and small molecules (tofacitinib, apremilast) are considered in detail. Special emphasis is placed on the important nuances of biological therapy: immunogenicity, drugs' survival and switch due to lack of efficacy. Invention of biologics signified a new era of moderate-to-severe psoriasis treatment. It became possible to achieve complete clinical remission more safely, which significantly improved the quality of life of patients. However, due to the unknown etiology of psoriasis, there is still no universal remedy that would allow to cure every patient, this fact makes scientists from all over the world keep conducting numerous clinical trials to find even more effective and safe therapeutic options.
اللغة: Russian
تدمد: 2313-6294
0042-4609
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::654cff9ad8ca3d49b0319ed5ae906f41Test
https://vestnikdv.ru/jour/article/viewFile/1162/1094Test
حقوق: OPEN
رقم الانضمام: edsair.doi.dedup.....654cff9ad8ca3d49b0319ed5ae906f41
قاعدة البيانات: OpenAIRE